Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Cash from Investing Activities for 6 consecutive years, with $83000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 143.23% to $83000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.1 million, a 975.7% decrease, with the full-year FY2024 number at -$568000.0, up 33.41% from a year prior.
  • Cash from Investing Activities was $83000.0 for Q3 2025 at Vivos Therapeutics, up from -$5.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $83000.0 in Q3 2025 to a low of -$5.9 million in Q2 2025.
  • A 5-year average of -$573578.9 and a median of -$192000.0 in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 19533.47% in 2021, then skyrocketed 143.23% in 2025.
  • Vivos Therapeutics' Cash from Investing Activities stood at -$382000.0 in 2021, then soared by 47.64% to -$200000.0 in 2022, then grew by 17.5% to -$165000.0 in 2023, then changed by 0.0% to -$165000.0 in 2024, then skyrocketed by 150.3% to $83000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cash from Investing Activities are $83000.0 (Q3 2025), -$5.9 million (Q2 2025), and -$122000.0 (Q1 2025).